Interpace Biosciences
Interpace Commences $30M Rights Offering
The company said the offering will help raise capital while allowing existing shareholders to maintain their proportional ownership in the company.
Interpace Biosciences Q3 Revenues Rise 15 Percent
The company attributed the revenue gains to higher reimbursement rates and greater clinical services volume for its thyroid cancer tests.
Interpace Biosciences Q2 Revenues More Than Double
The company attributed the higher revenues to increased reimbursement rates and greater clinical services volume for its cancer tests.
Interpace Biosciences Q1 Revenues Up 8 Percent
The company attributed the revenue increase to improved performance in its clinical services business and increased reimbursement rates for its cancer tests.
Interpace Biosciences to Review Strategic Alternatives
The company, which was recently delisted from the Nasdaq, began a reorganization earlier this year in order to cut $7.2 million in annual costs.
Jan 20, 2021
Interpace Bio Q3 Revenues Rise 6 Percent
Oct 20, 2020
Interpace Biosciences Q2 Revenues Decline 14 Percent
Jun 26, 2020
Interpace Biosciences Q1 Revenues Rise 53 Percent
Dec 20, 2019
Aug 13, 2019